Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Refractory Systemic Lupus Erythematosus
NCT06530849Phase 2Active, not recruiting
- Sponsor
- Gracell Biotechnologies
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GC012 in systemic lupus erythematosus (SLE), sponsored by Gracell Biotechnologies. Started Aug 2024; status: active, not recruiting.
02
Drugs
GC012
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06530849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530849.